Paliperidone Palmitate Intramuscular 3-Monthly Formulation: A Review in Schizophrenia

Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study

(2016) Adam J. Savitz et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values

(2015) Lik Hang N. Lee et al.   CNS DRUGS

Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia

(2015) Srihari Gopal et al.   CURRENT MEDICAL RESEARCH AND OPINION

Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study

(2015) Paulien Ravenstijn et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia

(2015) Joris Berwaerts et al.   JAMA Psychiatry

Long-Acting Injectable Formulations of New-Generation Antipsychotics: A Review from a Clinical Perspective

(2013) Anna-Sophia Rauch et al.   CNS DRUGS

Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia

(2013) Gabriel Kaplan et al.   Patient Preference and Adherence

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects

(2012) Alkomiet Hasan et al.   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Intramuscular Paliperidone Palmitate

(2010) Sheridan M. Hoy et al.   CNS DRUGS

The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements

(2009) R. W. Buchanan et al.   SCHIZOPHRENIA BULLETIN